William Daniel
Family Medicine · Manchester, TNNPI 1497851786
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $793 and has fallen 68.3% since, to $251 in 2025.
Across 232 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$685
- Novo Nordisk$494
- Astellas Pharma US Inc$352
- AstraZeneca$275
- Pfizer$201
- GSK$171
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,599100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $685 |
| Novo Nordisk | 33 | $494 |
| Astellas Pharma US Inc | 20 | $352 |
| AstraZeneca | 20 | $275 |
| Pfizer | 13 | $201 |
| GSK | 13 | $171 |
| Boehringer Ingelheim | 11 | $165 |
| Lilly USA, LLC | 10 | $156 |
| Otsuka America Pharmaceutical, Inc. | 9 | $142 |
| Xeris Pharmaceuticals, Inc. | 6 | $103 |
| Amgen | 5 | $95 |
| Merck | 7 | $92 |
| Novartis | 5 | $85 |
| Johnson & Johnson | 5 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $53 |
| Gilead | 2 | $47 |
| Boston Scientific | 2 | $47 |
| Dexcom, Inc. | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Abbott | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Sumitomo Pharma America, Inc. | 2 | $24 |
| Lundbeck LLC | 1 | $22 |
| Medtronic | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$3,599 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 84 | $81,019 |
| FarxigaDapagliflozin Propanediol | 101 | $79,402 |
| EliquisApixaban | 83 | $62,956 |
| JanuviaSitagliptin Phosphate | 74 | $59,090 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $50,277 |
| OzempicSemaglutide | 43 | $49,632 |
| RybelsusSemaglutide | 33 | $47,716 |
| TrulicityDulaglutide | 19 | $32,065 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $22,540 |
| MyrbetriqMirabegron | 26 | $21,669 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $21,637 |
| XareltoRivaroxaban | 19 | $17,262 |
| MounjaroTirzepatide | 16 | $16,569 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $13,066 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $11,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Nexium | $275 | $115,523171 claims |
| Novo NordiskOzempic, Rybelsus, Levemir, Novolog | $494 | $107,415105 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $165 | $87,74298 claims |
| PfizerEliquis | $201 | $62,95683 claims |
| MerckJanuvia | $92 | $59,09074 claims |
| GSKTrelegy Ellipta | $171 | $50,27761 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $156 | $48,63435 claims |
| Astellas Pharma US IncMyrbetriq | $352 | $21,66926 claims |
| Johnson & JohnsonXarelto | $66 | $17,26219 claims |
| AbbVieSynthroid | $685 | $4,21961 claims |
| Sanofi-aventis U.S. LLCLantus | $15 | $2,53722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Manchester
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
- Meredith SchweitzerAntioch$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.